Diagnostics for Better care, Everywhere. En Carta Diagnostics is a synthetic-biology biotech company leveraging patented technologies to decentralise highly reliable molecular diagnostic solutions.
Location: France, Ile-de-France, Paris
Employees: 1-10
Total raised: $1.63M
Investors 1
| Date | Name | Website |
| 01.07.2025 | Business A... | business-a... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 23.05.2024 | Pre-Seed | $1.63M | - |
Mentions in press and media 6
| Date | Title | Description |
| 13.07.2026 | Startup of the Week: En Carta | En Carta develops molecular diagnostic platforms designed for home use: as easy to use as a rapid test, delivering results in 30 minutes with the same accuracy as a lab test. They already hold FDA Breakthrough Device Designation for the ear... |
| 24.05.2024 | En Carta Diagnostics: A Game-Changer in Lyme Disease Detection | En Carta Diagnostics, a pioneering startup based in Paris, France, has recently secured a substantial €1.5 million in Pre-Seed funding to advance its cutting-edge molecular diagnostic technology. Specializing in rapid Point-of-Care (POC) di... |
| 23.05.2024 | En Carta Diagnostics secures €1.5M for rapid Lyme disease diagnostic kits | En Carta Diagnostics, a deeptech startup developing rapid Point-of-Care (POC) molecular diagnostics kits, today announces €1.5 million in Pre-Seed funding. The company is addressing Lyme disease as its first application due to this disorder... |
| 22.05.2024 | En Carta Diagnostics Raises €1.5M in Pre-Seed Funding | En Carta Diagnostics, a Paris, France-based startup developing rapid point-of-care (POC) molecular diagnostics kits, raised €1.5M in Pre-Seed funding. The round was led by CentraleSupélec Venture with participation from undisclosed angles. ... |
| - | En Carta Diagnostics | “En Carta Diagnostics develops molecular tests, as easy to use as rapid tests, as precise as a PCR machine. We currently offer Lyme disease early detection kits and CT/NG - Chlamydia and Gonorrhea kits.” |
| - | En Carta Diagnostics | “En Carta provides low cost and high accuracy paper based diagnostics. Our first product is a SARS-CoV-2 or COVID-19 Diagnostic” |